Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Executive Summary

UPDATED on 7/30/2019

Leaders in Pharmaceutical Business Intelligence (LPBI) Group

The Challenge

“Today, there is a digital information explosion in the fields of Life Sciences and Medicine,” said Aviva Lev-Ari, PhD., RN, and founder of Leaders in Pharmaceutical Business Intelligence (LPBI) Group. “To manage that challenge, we are responding to the needs of our multi-faceted audiences in order to guard against information obsolescence through transformational technologies and solutions.”

Our Vision:

LPBI Group generates vast scientific content via industry thought leaders through multiple platforms and makes it universally accessible.

About LPBI Group

Leaders in Pharmaceutical Business Intelligence Group (“LPBI Group”) is a leading, electronic scientific content-creation venture, offering real-time, original scientific content through advanced platform architecture methodologies since 2012. The company’s commitment is to synthesize, analyze and interpret complex, medical and scientific disease information through electronic publishing venues via the cloud to advance the knowledge and research efforts of the scientific and business community.

LPBI Group was created in 2012 by Dr. Aviva Lev-Ari, Ph.D., R.N. The Group has evolved into three, interrelated domains – an open-access online scientific journal, a series of 16 BioMed e-books and real-time press coverage of BioMed scientific and medical conferences. Through this transformative offering, the Group effectively meets and exceeds the information needs of researchers, scientists and industry pharmaceutical and biotechnology executives by offering real-time and currently available medical and scientific information on any subject as well as cutting-edge biomedical research innovation widely available to the scientific and non-research community. The method of curation includes synthesis, analysis and interpretation of complex medical and scientific areas.

Year over year, there is increased readership of highly valued content, which equates to more than 5,900 scientific articles with over 1.8 million readers in the online scientific journal.

Unique, Experienced Team

The Group employs a team of highly experienced individuals in Life Sciences, particularly within the key domains of BioMedicine, Biotechnology, Pharmaco-therapy, Medical and Information Technology, Health Care and the Life Sciences/Medicine connection.

All members of the LPBI Group team have a wealth of expertise and experience in Life Sciences and have been trained to master the methodology of scientific curation used in the articles. Those individuals include senior MDs, MD/PhDs, PharmDs and senior PhDs who expressed interest in medical writing and clinical interpretation of basic research, translational research and interpretation of clinical trials outcomes.

• Medical Doctors: Dr. Larry H. Bernstein (retired), Dr. Justin Pearlman (Central Maine Medical Center)
• Doctors of Philosophy: Dr. Justin Pearlman, Dr. Stephen Williams, Dr. Sudipta Saha, Dr. Ritu Saxena, Dr. Tilda Barliya, Dr. Irina Robu, Dr. Dror Nir, Dr. Aviva Lev-Ari
• Professors in Academia: Prof. Marcus W. Feldman (Stanford University), Prof. Stephen J. Williams (Temple University), Prof. Sudipta Saha (Amity University Noida, Uttar Pradesh, India), Dr. Irina Robu (Windsor, Ontario, Canada), Adam Sonnenberg, PhD(c), Boston University
• Executives in Biotechnology and Information Technology Industries: Amnon Danzig, MBA, Europe-Asia (business development consultant with specialization in Strategy, Corporate Finance and Human Capital, published author on Value Creation concepts), Rick Mandahl, MBA, Americas (business development consultant in emerging technologies with Biotech, Information Technology focus), Ritu Saxena (Astellas Pharma), Gail S. Thornton, M.A., PhD(c), (Merck & Co., USA, communications consultant, published author on health, wellness, communications strategy)

Scientific e-Books Source

The 16 BioMed e-books include topics focused on medical science, diagnostics and therapy. The books’ sustainability is maintained by online continuing updates made to articles in the online scientific journal. Each of the scientific e-books contain an abbreviated electronic table of contents, which consists of ‘live’ links from each article in the e-book to the article in the online scientific journal. Readers of the e-books can click on this link to receive the most, updated “State of Science” for each topic. This unique feature makes the e-books relevant and provides a timely source of knowledge and reference.

Highly qualified content consultants, who are senior MDs, MD/PhDs and Professors, are involved in the production and clinical interpretations of the curations. The topics for curation and the contents of the books are uniquely created and carefully edited. Dr. Aviva Lev-Ari as the editor-in-chief leads this multidisciplinary content compilation using her diverse areas of technical training and experience. It should be noted that all of LPBI’s material could, in principle, be translated into other languages.

Journal Ontology

Our intellectual property consists of three classes of Intellectual property assets as described in detail with live links in the following article:

eScientific Publishing a Case in Point: Evolution of Platform Architecture Methodologies and of Intellectual Property Development (Content Creation by Curation) Business Model

https://pharmaceuticalintelligence.com/2019/02/04/escientific-publishing-a-case-in-point-evolution-of-platform-architecture-methodologies-and-of-intellectual-property-development-content-creation-by-curation-business-model/

Three Classes of Intellectual Property Assets

These assets include an open-access online scientific journal with curated, current biomedical research; a series of 16 BioMed e-books available via Amazon in five specialties of Medicine: Cardiovascular, Genomic Medicine (a subset of Precision Medicine), Cancer, Immunology and Precision Medicine; and real-time curation of biotech and medical conferences yielding an e-Proceedings at the end of the conference in one click operation.

For example, Genomic Medicine, as an emerging medical discipline, is making an impact in the fields of oncology, pharmacology, rare and undiagnosed diseases and infectious disease. This field involves using genomic information about an individual as part of their clinical care (e.g., for diagnostic or therapeutic decision-making) and the health outcomes and policy implications of that clinical use.

The open-access online scientific journal ontology is a relational and hierarchical knowledge base allowing for expansion of the content creation process between the journal and the series of BioMed e-books, but it is not limited to these two areas. For example, one of the research categories, entitled “Interviews with Scientific Leaders,” includes in its growth plan the option of podcasts, an audio media component that will supplement the video media component used extensively in the BioMed e-Series.

The Group’s business is scalable, and the skill set needed for curation of scientific findings for clinical interpretations, as well as in other disciplines can be augmented by appropriate training in the curation methodology to be offered to experts in many fields. In our seven years together, the Group’s writers and editors generated a remarkable synergy among experts, authors and writers, which yields outstanding collaboration in producing these curations. There are many post-doctoral individuals in the biotechnology industry as well as academia who can serve as experts, authors and writers in continuing the Group’s operations, following appropriate onboarding.